Eyal Shahar examines the Pfizer mRNA Covid vaccine trial conducted five years ago, questioning its design and trustworthiness. It discusses the methodology and results of the trial, focuses on the initial spike in vaccine effectiveness, and highlights issues related to underreported Covid cases among participants.
1. Trial Overview:
• The Pfizer vaccine trial involved about 40,000 participants divided equally between receiving the vaccine and a placebo.
• Participants reported symptoms during the trial, and if they reported any Covid-like symptoms, a PCR test was conducted to confirm if they had Covid.
2. Suspicious Effectiveness Observations:
• The effectiveness of the vaccine reportedly jumped from 50% to 90% just days after the second dose, a change questioned for its plausibility.
• There are concerns that this sudden increase raises doubts about the reliability of the results.
3. Potential Undercounting of Cases:
• Participants often reported side effects that overlapped with Covid symptoms, particularly after the second dose.
• It was noted that not all participants with such symptoms received PCR tests to rule out Covid, leading to concerns about missing numerous cases.
4. Analysis of Reporting Practices:
• Investigators were given discretion on whether to test participants showing symptoms, which may have led to underreported Covid cases among vaccinated individuals.
• The data presented in the FDA briefing documents suggest a significant discrepancy in the number of suspected but unconfirmed Covid cases between vaccine and placebo groups within the week of vaccination.
5. Comparative Analysis of Symptoms:
• Vaccine recipients were reported to show more non-Covid symptoms in the immediate week after vaccination due to vaccine reactogenicity but fewer in later follow-ups.
• This raises several questions, including whether the vaccine not only affected Covid but potentially impacted other non-Covid symptoms.
6. Concerns Over Data Transparency:
• There are significant questions about how information regarding the reports and cases was communicated, particularly in the lengthy FDA documents.
• The omission of crucial details in the main research paper may lead to misunderstandings regarding the safety and efficacy of the vaccine.
7. General Skepticism:
• The article emphasizes the author’s skepticism about the trial results, questioning how much faith can be placed in the published data, especially after witnessing adverse outcomes in real-world vaccination scenarios.
Eyal Shahar's analysis reveals several possible flaws and hidden details in the Pfizer vaccine trial, raising concerns about the credibility and overall effectiveness of the vaccine. The increase in reported effectiveness shortly after vaccination and the handling of participant symptom reporting are critical points of focus. The discussion calls for a review of the methodologies used in large-scale vaccine trials and highlights the importance of transparency in clinical research findings.
https://brownstone.org/articles/miracles-in-the-infamous-pfizer-trial/